This study demonstrates that the radiation exposure to the patient can be significantly and simply reduced using modified dose acquisition settings for TAVI without affecting procedural outcomes.

Follow-up was performed at 30 days, 6 months, 1 year, and yearly thereafter. All events were defined according to VARC criteria. Results: Women undergoing TAVI were older compared to men (80.8Ϯ5.9 vs. 78.2Ϯ8.6 years, pϭ0.01), but had less coronary and peripheral arterial disease and higher ejection fraction. The logistic EuroSCORE was comparable (23.1Ϯ13.8% vs. 25.7Ϯ16.2%, pϭ0.20). Aortic annular diameter (22.7Ϯ1.9 vs. 24.2Ϯ2.2 mm, pϽ0.001) and valve size were smaller in women. After TAVI, mean residual aortic pressure gradient was similar (9.4Ϯ6.2 vs. 8.7Ϯ4.4, pϭ0.38), but significant (Ն2/4) paravalvular aortic regurgitation was less frequent in women (15.1% vs. 28.1%, pϭ0.01), resulting in a higher device success rate. Despite more frequent peri-procedural life-threatening bleeding and major vascular complications in women (11.9% vs. 4.2%, pϭ0.04, and 9.5% vs. 0%, pϭ0.002), mortality was numerically lower in women at 30-days (3.2% vs. 5.2%, pϭ0.44) and significantly lower at 6 months (6.6% vs. 15.5%, pϭ0.04) and one year (7.7% vs. 21.4%, pϭ0.01). Survival rates at 3 years were 83.1% in women and 60.5% in men (log-rank pϭ0.02). Conclusions: Women undergoing TAVI are older but have less co-morbidities compared to men. Bleeding and vascular complications are more common in women, but significant aortic regurgitation occurs less. Women have improved mid-term survival after TAVI and thus appear to obtain a greater benefit from this evolving procedure.